Latest Pharma Insights
US FDA Advisers Wrestle With How To Validate Pathogen-Agnostic Sequencing Before The Next Pandemic
The Microbiology Devices Panel took no votes on pathogen-agnostic sequencing, but its talk of validation, thresholds and change control may preview how FDA reviews future tests.
Medtech Insight - November 20, 2026
The Microbiology Devices Panel took no votes on pathogen-agnostic sequencing, but its talk of validation, thresholds and change control may preview how FDA reviews future tests.
Medtech Insight - November 20, 2026
The Insights Room: Are EU Medtechs Ready For Continuous Monitoring?
In this episode of the Medtech Insight podcast, we discuss 2027's biggest potential changes for the medtech sector with Veeva MedTech's Diogo Geraldes.
Medtech Insight - November 20, 2026
In this episode of the Medtech Insight podcast, we discuss 2027's biggest potential changes for the medtech sector with Veeva MedTech's Diogo Geraldes.
Medtech Insight - November 20, 2026
After Biggest Ever Biotech IPO, Parabilis Focuses On Building For The Long-Term
Chief business and strategic officer, Helen Ho, laid out the long-term vision for the company and its Helicon platform at the Evaluate Leaders’ Forum.
Scrip - November 20, 2026
Chief business and strategic officer, Helen Ho, laid out the long-term vision for the company and its Helicon platform at the Evaluate Leaders’ Forum.
Scrip - November 20, 2026
Bayer BD Chief: Best Time To Partner Is Early
Juergen Eckhardt tells Scrip why the German major prefers to work with biotechs at the start of their development journey.
Scrip - November 20, 2026
Juergen Eckhardt tells Scrip why the German major prefers to work with biotechs at the start of their development journey.
Scrip - November 20, 2026
India Wants To Climb The Global Drug Development Ladder, But Home-Grown Innovation Lags
India drug development partnerships with global drugmakers remain largely fee-for-service, an OPPI-EY report says, as industry leaders urge more trials and innovation.
Scrip - November 20, 2026
India drug development partnerships with global drugmakers remain largely fee-for-service, an OPPI-EY report says, as industry leaders urge more trials and innovation.
Scrip - November 20, 2026
FDA Issues Aflibercept CRL To SamChunDang Pharm
SamChunDang Pharm has been hit with a CRL from the US FDA over its SCD411 proposed aflibercept biosimilar to Eylea. US marketing partner Fresenius Kabi told Generics Bulletin the pair were “committed to addressing all points raised.”
Generics Bulletin - November 20, 2026
SamChunDang Pharm has been hit with a CRL from the US FDA over its SCD411 proposed aflibercept biosimilar to Eylea. US marketing partner Fresenius Kabi told Generics Bulletin the pair were “committed to addressing all points raised.”
Generics Bulletin - November 20, 2026
MPP Looks For Xofluza Licensee In Latin America And Caribbean
After granting multiple licenses for generic versions of flu treatment Xofluza for LMICs in September, the Medicines Patent Pool is looking for a further partner on baloxavir marboxil based in the Latin American and Caribbean region.
Generics Bulletin - November 20, 2026
After granting multiple licenses for generic versions of flu treatment Xofluza for LMICs in September, the Medicines Patent Pool is looking for a further partner on baloxavir marboxil based in the Latin American and Caribbean region.
Generics Bulletin - November 20, 2026
FDA Proposes Withdrawing Salerno’s Liquid Simvastatin Over Missing Reports
After proposing to withdraw its Flolipid 505(b)(2) liquid simvastatin product, the FDA has offered Salerno an opportunity for a hearing.
Generics Bulletin - November 20, 2026
After proposing to withdraw its Flolipid 505(b)(2) liquid simvastatin product, the FDA has offered Salerno an opportunity for a hearing.
Generics Bulletin - November 20, 2026
Two-Thirds Of UK Adults Back More Rx-To-OTC Switches
PAGB’s latest Self-Care Census finds 68% of UK adults want more medicines without prescription. UK regulator MHRA links the findings to reclassification and women’s health.
HBW Insight - November 20, 2026
PAGB’s latest Self-Care Census finds 68% of UK adults want more medicines without prescription. UK regulator MHRA links the findings to reclassification and women’s health.
HBW Insight - November 20, 2026
UK Rare Disease Science Is Outrunning Its Reimbursement System, Industry Leaders Warn
The UK’s rare disease science is world-class yet speakers at the Oxford-Harrington symposium said weak reimbursement and access are leaving some companies unsure how far to invest in UK trials and launches.
In Vivo - November 20, 2026
The UK’s rare disease science is world-class yet speakers at the Oxford-Harrington symposium said weak reimbursement and access are leaving some companies unsure how far to invest in UK trials and launches.
In Vivo - November 20, 2026
Global Regulators Collaborate On AI Medtech Directory, Plan Worldwide Warning System
Database from HealthAI network aims to improve international reliance by making information on all approved AI devices publicly available.
Medtech Insight - November 20, 2026
Database from HealthAI network aims to improve international reliance by making information on all approved AI devices publicly available.
Medtech Insight - November 20, 2026
US FDA May Get Another Acting Commissioner Before Democrats Control Confirmation
An acting FDA commissioner will have less clout with Capitol Hill just as the legislative phase of the PDUFA reauthorization begins and incoming Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders is questioning industry-funded regulation.
HBW Insight - November 20, 2026
An acting FDA commissioner will have less clout with Capitol Hill just as the legislative phase of the PDUFA reauthorization begins and incoming Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders is questioning industry-funded regulation.
HBW Insight - November 20, 2026
Omnibus VI Is Final: Cosmetics Companies Should Review Label Plans
Cosmetics companies in the EU have until 2030 to meet revised chemical labeling rules, but the Council’s Omnibus VI approval leaves the deadlines for finished cosmetic products, including the CMR phase-outs, unchanged.
HBW Insight - November 20, 2026
Cosmetics companies in the EU have until 2030 to meet revised chemical labeling rules, but the Council’s Omnibus VI approval leaves the deadlines for finished cosmetic products, including the CMR phase-outs, unchanged.
HBW Insight - November 20, 2026
After Biggest Ever Biotech IPO, Parabilis Focuses On Building For The Long-Term
Chief business and strategic officer, Helen Ho, laid out the long-term vision for the company and its Helicon platform at the Evaluate Leaders’ Forum.
Scrip - November 20, 2026
Chief business and strategic officer, Helen Ho, laid out the long-term vision for the company and its Helicon platform at the Evaluate Leaders’ Forum.
Scrip - November 20, 2026
Bayer BD Chief: Best Time To Partner Is Early
Juergen Eckhardt tells Scrip why the German major prefers to work with biotechs at the start of their development journey.
Scrip - November 20, 2026
Juergen Eckhardt tells Scrip why the German major prefers to work with biotechs at the start of their development journey.
Scrip - November 20, 2026
India Wants To Climb The Global Drug Development Ladder, But Home-Grown Innovation Lags
India drug development partnerships with global drugmakers remain largely fee-for-service, an OPPI-EY report says, as industry leaders urge more trials and innovation.
Scrip - November 20, 2026
India drug development partnerships with global drugmakers remain largely fee-for-service, an OPPI-EY report says, as industry leaders urge more trials and innovation.
Scrip - November 20, 2026
US FDA Advisers Wrestle With How To Validate Pathogen-Agnostic Sequencing Before The Next Pandemic
The Microbiology Devices Panel took no votes on pathogen-agnostic sequencing, but its talk of validation, thresholds and change control may preview how FDA reviews future tests.
Medtech Insight - November 20, 2026
The Microbiology Devices Panel took no votes on pathogen-agnostic sequencing, but its talk of validation, thresholds and change control may preview how FDA reviews future tests.
Medtech Insight - November 20, 2026
The Insights Room: Are EU Medtechs Ready For Continuous Monitoring?
In this episode of the Medtech Insight podcast, we discuss 2027's biggest potential changes for the medtech sector with Veeva MedTech's Diogo Geraldes.
Medtech Insight - November 20, 2026
In this episode of the Medtech Insight podcast, we discuss 2027's biggest potential changes for the medtech sector with Veeva MedTech's Diogo Geraldes.
Medtech Insight - November 20, 2026
Global Regulators Collaborate On AI Medtech Directory, Plan Worldwide Warning System
Database from HealthAI network aims to improve international reliance by making information on all approved AI devices publicly available.
Medtech Insight - November 20, 2026
Database from HealthAI network aims to improve international reliance by making information on all approved AI devices publicly available.
Medtech Insight - November 20, 2026
Two-Thirds Of UK Adults Back More Rx-To-OTC Switches
PAGB’s latest Self-Care Census finds 68% of UK adults want more medicines without prescription. UK regulator MHRA links the findings to reclassification and women’s health.
HBW Insight - November 20, 2026
PAGB’s latest Self-Care Census finds 68% of UK adults want more medicines without prescription. UK regulator MHRA links the findings to reclassification and women’s health.
HBW Insight - November 20, 2026
US FDA May Get Another Acting Commissioner Before Democrats Control Confirmation
An acting FDA commissioner will have less clout with Capitol Hill just as the legislative phase of the PDUFA reauthorization begins and incoming Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders is questioning industry-funded regulation.
HBW Insight - November 20, 2026
An acting FDA commissioner will have less clout with Capitol Hill just as the legislative phase of the PDUFA reauthorization begins and incoming Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders is questioning industry-funded regulation.
HBW Insight - November 20, 2026
Omnibus VI Is Final: Cosmetics Companies Should Review Label Plans
Cosmetics companies in the EU have until 2030 to meet revised chemical labeling rules, but the Council’s Omnibus VI approval leaves the deadlines for finished cosmetic products, including the CMR phase-outs, unchanged.
HBW Insight - November 20, 2026
Cosmetics companies in the EU have until 2030 to meet revised chemical labeling rules, but the Council’s Omnibus VI approval leaves the deadlines for finished cosmetic products, including the CMR phase-outs, unchanged.
HBW Insight - November 20, 2026
FDA Issues Aflibercept CRL To SamChunDang Pharm
SamChunDang Pharm has been hit with a CRL from the US FDA over its SCD411 proposed aflibercept biosimilar to Eylea. US marketing partner Fresenius Kabi told Generics Bulletin the pair were “committed to addressing all points raised.”
Generics Bulletin - November 20, 2026
SamChunDang Pharm has been hit with a CRL from the US FDA over its SCD411 proposed aflibercept biosimilar to Eylea. US marketing partner Fresenius Kabi told Generics Bulletin the pair were “committed to addressing all points raised.”
Generics Bulletin - November 20, 2026
MPP Looks For Xofluza Licensee In Latin America And Caribbean
After granting multiple licenses for generic versions of flu treatment Xofluza for LMICs in September, the Medicines Patent Pool is looking for a further partner on baloxavir marboxil based in the Latin American and Caribbean region.
Generics Bulletin - November 20, 2026
After granting multiple licenses for generic versions of flu treatment Xofluza for LMICs in September, the Medicines Patent Pool is looking for a further partner on baloxavir marboxil based in the Latin American and Caribbean region.
Generics Bulletin - November 20, 2026
FDA Proposes Withdrawing Salerno’s Liquid Simvastatin Over Missing Reports
After proposing to withdraw its Flolipid 505(b)(2) liquid simvastatin product, the FDA has offered Salerno an opportunity for a hearing.
Generics Bulletin - November 20, 2026
After proposing to withdraw its Flolipid 505(b)(2) liquid simvastatin product, the FDA has offered Salerno an opportunity for a hearing.
Generics Bulletin - November 20, 2026
UK Rare Disease Science Is Outrunning Its Reimbursement System, Industry Leaders Warn
The UK’s rare disease science is world-class yet speakers at the Oxford-Harrington symposium said weak reimbursement and access are leaving some companies unsure how far to invest in UK trials and launches.
In Vivo - November 20, 2026
The UK’s rare disease science is world-class yet speakers at the Oxford-Harrington symposium said weak reimbursement and access are leaving some companies unsure how far to invest in UK trials and launches.
In Vivo - November 20, 2026




